3 Best Stocks to Buy Now, 8/9/2023, According to Top Analysts
Stock Analysis & Ideas

3 Best Stocks to Buy Now, 8/9/2023, According to Top Analysts

Which stocks are best to buy now? According to top Wall Street analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating today and has a significant upside as well.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by top-ranking analysts.

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

Revance Therapeutics (NASDAQ:RVNC) – It is a biotechnology company focusing on the development and commercialization of aesthetic and therapeutic offerings. Today, H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on the stock with a price target of $41. The stock has received Buy ratings from all three top analysts who have recently rated it. Collectively, their 12-month price targets imply an upside of nearly 83.4%.

SeaWorld Entertainment (NYSE:SEAS– It is a leading theme park and entertainment company. Today, B. Riley Financial analyst Eric Wold reiterated a Buy rating on the stock with a price target of $78. The stock has received Buy ratings from all four top analysts who have recently rated it. Collectively, their 12-month price targets imply an upside of nearly 35.55%.

Arcutis Biotherapeutics (NASDAQ:ARQT) – It is a medical dermatology company focused on the treatment of immune-mediated dermatological diseases and conditions. Today, Mizuho Securities analyst Uy Ear reiterated a Buy rating and a price target of $57. The stock has received Buy ratings from all four top analysts who have recently rated it. Collectively, their 12-month price targets imply an upside of nearly 367.96%.

Who are the Top Analysts?

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. See real-time analyst rankings and learn more about the performance of top analysts on TipRanks’ Top Wall Street Analysts page.

Disclosure

Related Articles
TheFlyArcutis announces new pooled subgroup analysis results from INTEGUMENT-1 trial
TheFlyArcutis Biotherapeutics announces FDA accepted its sNDA for ZORYVE foam
TheFlyArcutis Biotherapeutics annonnces publication of ZORYVE in JAMA Dermatology
Go Ad-Free with Our App